Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Nanjing Medlander Medical Technology CoSHSE:688273 -2.66%81 5-Year Yield-on-Cost % is 2.63 as of Aug. 23, 2026, which is 4% above its 10-year median of 2.52. GuruFocus rates SHSE:688273 with a GF Score™ of 81/100 and a GF Value™ of ¥37.16 (Modestly Undervalued). The stock has 7 warning signs investors should review. Among 315 Medical Devices & Instruments companies, Nanjing Medlander Medical Technology Co ranks better than 53.97% on this metric.
SHSE:688273's 5-Year Yield-on-Cost % is ranked better than 53.97% of 315
companies
in the Medical Devices & Instruments industry
Industry Median: 2.38
vs SHSE:688273: 2.63
Nanjing Medlander Medical Technology Co (SHSE:688273) 5-Year Yield-on-Cost % Explanation
Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.
Nanjing Medlander Medical Technology Co 5-Year Yield-on-Cost % Related Terms
SHSE:688273 vs ABT, SYK, MDT: 5-Year Yield-on-Cost % Comparison
For the Medical Devices subindustry, Nanjing Medlander Medical Technology Co's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Nanjing Medlander Medical Technology Co 5-Year Yield-on-Cost % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Nanjing Medlander Medical Technology Co's 5-Year Yield-on-Cost % distribution charts can be found below:
* The bar in red indicates where Nanjing Medlander Medical Technology Co's 5-Year Yield-on-Cost % falls into.
Nanjing Medlander Medical Technology Co 5-Year Yield-on-Cost % Calculation
Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.
Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.
Nanjing Medlander Medical Technology Co (SHSE:688273) has a 5-Year Yield-on-Cost % of 2.63 as of Aug. 23, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Nanjing Medlander Medical Technology Co and its competitors. This is near median its historical median of 2.52. Over the past decade, Nanjing Medlander Medical Technology Co's 5-Year Yield-on-Cost % has ranged from 1.07 to 4.72. According to the industry distribution chart, Nanjing Medlander Medical Technology Co ranks #145 out of 315 companies in the Medical Devices & Instruments industry, placing it in the top 46%.
Is Nanjing Medlander Medical Technology Co's 5-Year Yield-on-Cost % too high?
Nanjing Medlander Medical Technology Co's current 5-Year Yield-on-Cost % of 2.63 is near median its 10-year median of 2.52. Over the past 10 years, this metric has ranged from a low of 1.07 to a high of 4.72. The Medical Devices & Instruments industry median 5-Year Yield-on-Cost % is 2.38. Nanjing Medlander Medical Technology Co's value of 2.63 is 10.5% above this industry median. Based on the distribution chart, Nanjing Medlander Medical Technology Co ranks #145 out of 315 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Nanjing Medlander Medical Technology Co has a GF Score™ of 81/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Nanjing Medlander Medical Technology Co's 5-Year Yield-on-Cost % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Nanjing Medlander Medical Technology Co ranks #145 out of 315 companies for 5-Year Yield-on-Cost %. This puts Nanjing Medlander Medical Technology Co in the upper half of its industry. The industry median 5-Year Yield-on-Cost % is 2.38. Nanjing Medlander Medical Technology Co's value of 2.63 is 10.5% above this benchmark. Historically, Nanjing Medlander Medical Technology Co's own 5-Year Yield-on-Cost % has ranged from 1.07 to 4.72 over the past decade. While the company's 10-year median is 2.52 vs. the industry median of 2.38, Nanjing Medlander Medical Technology Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Medical Devices & Instruments company?
The median 5-Year Yield-on-Cost % among Medical Devices & Instruments companies is 2.38, based on 315 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Nanjing Medlander Medical Technology Co's current 5-Year Yield-on-Cost % of 2.63 is 10.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Nanjing Medlander Medical Technology Co and its competitors. For the Medical Devices & Instruments industry, the median 5-Year Yield-on-Cost % is 2.38 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Nanjing Medlander Medical Technology Co's current 5-Year Yield-on-Cost % is 2.63, which is near median its own 10-year median of 2.52. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nanjing Medlander Medical Technology Co stock overvalued right now?
Based on GuruFocus' analysis, Nanjing Medlander Medical Technology Co (SHSE:688273) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥37.16, compared to a current price of ¥30.41 — trading 18.2% below its estimated fair value. The current 5-Year Yield-on-Cost % is 2.63, which is near median its 10-year median of 2.52 and 10.5% above the Medical Devices & Instruments industry median of 2.38. Nanjing Medlander Medical Technology Co's overall GF Score™ is 81/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For Nanjing Medlander Medical Technology Co (SHSE:688273), the current 5-Year Yield-on-Cost % is 2.63 as of Aug. 23, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Nanjing Medlander Medical Technology Co (SHSE:688273) Overvalued in 2026?
Based on GuruFocus' analysis, Nanjing Medlander Medical Technology Co stock appears to be undervalued.
The current stock price of ¥30.41 is trading 18.2% below its estimated GF Value™ of ¥37.16.
GuruFocus considers Nanjing Medlander Medical Technology Co to be Modestly Undervalued.
Key valuation signals for SHSE:688273:
5-Year Yield-on-Cost %: 2.63 (near median its 10-year median of 2.52)
GF Value™: ¥37.16 vs. price of ¥30.41 (18.2% below fair value)
Industry Position: 10.5% above the Medical Devices & Instruments median (#145 of 315)
No single metric tells the full story. See the SHSE:688273 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Nanjing Medlander Medical Technology Co Ltd is engaged in the research and development, production, sales, and service of related products in the field of pelvic floor and postpartum rehabilitation. Its products mainly include: biostimulation feedback instrument, color ultrasound diagnosis and evaluation system, magnetic stimulator, high-frequency evaluation electrocautery instrument, pelvic floor training instrument, portable postpartum recovery instrument, home pelvic floor rehabilitation therapy instrument, etc., which are widely used in obstetrics and gynecology, pelvic floor rehabilitation center, urology, anorectal department and other hospital departments.
81GF Score
Get the complete analysis for SHSE:688273
5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:688273 has been successfully added to your 
